Relmada Therapeutics Stock (NASDAQ: RLMD)

Relmada Therapeutics

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Dollar.Burning.Shutterstock

Biotech

News

Health Care

Movers

Trading Ideas

General

RLMD

Relmada Therapeutics reports interim analysis of the Phase 3 Reliance II study for REL-1017 in major depressive disorder, indicating futility in meeting efficacy goals.

Relmada Therapeutics Stock Plummets Losing 80% Value - Here&#39;s Why

Wall-Street-ai7-1

Equities

Eurozone

Commodities

Intraday Update

Markets

CCRN

CNEY

CURV

PSQH

Nasdaq Surges 150 Points; ISM Services PMI Falls In November

Warning Signs of Extreme Valuations

Earnings

CYCN

ORIS

Dow Gains 250 Points; Salesforce Shares Jump After Q3 Results

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics Inc

Press Releases

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Relmada Therapeutics to Present at Jefferies London Healthcare Conference

Legal

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Artelo Biosciences

Aytu BioPharma

Biofrontera

Cingulate

CNS Pharma

China Pharma Holding

Enveric Biosciences

Evoke Pharma

Eyenovia

Hoth Therapeutics

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lyra Therapeutics

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

ProPhase Labs

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

Talphera

Traws Pharma

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

TherapeuticsMD

Virpax Pharmaceuticals, Inc. - Common Stock

Virpax Pharmaceuticals

Mizuho

Leerink Partners

Jefferies

Goldman Sachs

RELMADA THERAPEUTICS by Relmada Therapeutics, Inc.

Comments

Relmada Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga